Evidence map›Paper›PMID 24957825›Full record

ArticleAntimicrobial agents and chemotherapy2014

Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.

B J Werth, M E Steed, C E Ireland, T T Tran, P Nonejuie, B E Murray, W E Rose, G Sakoulas, J Pogliano, C A Arias and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Acquisition of Daptomycin Resistance byFrontiers in microbiology · 2022
    Article
  14. Article
  15. Alternatives to Fight Vancomycin-ResistantAntibiotics (Basel, Switzerland) · 2021
    Review
  16. Dalbavancin exposure in vitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2021
    Article
  17. Daptomycin Resistance Occurs Predominantly inFrontiers in microbiology · 2021
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

B J WerthAnti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
M E SteedUniversity of Kansas School of Pharmacy, Lawrence, Kansas, USA.
C E IrelandAnti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
T T TranDepartment of Internal Medicine, Division of Infectious Diseases, University of Texas Medical School, Houston, Texas, USA.
P NonejuieUniversity of California San Diego, Division of Biology, La Jolla, California, USA.
B E MurrayDepartment of Internal Medicine, Division of Infectious Diseases, University of Texas Medical School, Houston, Texas, USA Department of Microbiology and Molecular Genetics, University of Texas Medical School, Houston, Texas, USA.
W E RoseUniversity of Wisconsin-Madison School of Pharmacy, Madison, Wisconsin, USA.
G SakoulasUniversity of California San Diego School of Medicine, La Jolla, California, USA.
J PoglianoUniversity of California San Diego, Division of Biology, La Jolla, California, USA.
C A AriasDepartment of Internal Medicine, Division of Infectious Diseases, University of Texas Medical School, Houston, Texas, USA Department of Microbiology and Molecular Genetics, University of Texas Medical School, Houston, Texas, USA Molecular Genetics and Antimicrobial Unit, Universidad El Bosque, Bogota, Colombia.
M J RybakAnti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA School of Medicine, Wayne State University, Detroit, Michigan, USA m.rybak@wayne.edu.
The University of Texas at Austin · USUniversity of California, San Diego · USEugene Applebaum College of Pharmacy and Health Sciences · USUniversity of Kansas · USUniversity of Wisconsin–Madison · USWayne State University · US

Funding

Molecular Mechanisms Of Daptomycin Resistance In EnterococciR01AI093749 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2011 to 2015
$1.9M
NIAID NIH HHS R01 AI093749PHS HHS R21A1092055-01
6 · The paper itself

Abstract

Daptomycin is used off-label for enterococcal infections; however, dosing targets for resistance prevention remain undefined. Doses of 4 to 6 mg/kg of body weight/day approved for staphylococci are likely inadequate against enterococci due to reduced susceptibility. We modeled daptomycin regimens in vitro to determine the minimum exposure to prevent daptomycin resistance (Dapr) in enterococci. Daptomycin simulations of 4 to 12 mg/kg/day (maximum concentration of drug in serum [Cmax] of 57.8, 93.9, 123.3, 141.1, and 183.7 mg/liter; half-life [t1/2] of 8 h) were tested against one Enterococcus faecium strain (S447) and one Enterococcus faecalis strain (S613) in a simulated endocardial vegetation pharmacokinetic/pharmacodynamic model over 14 days. Samples were plated on media containing 3× the MIC of daptomycin to detect Dapr. Mutations in genes encoding proteins associated with cell envelope homeostasis (yycFG and liaFSR) and phospholipid metabolism (cardiolipin synthase [cls] and cyclopropane fatty acid synthetase [cfa]) were investigated in Dapr derivatives. Dapr derivatives were assessed for changes in susceptibility, surface charge, membrane depolarization, cell wall thickness (CWT), and growth rate. Strains S447 and S613 developed Dapr after simulations of 4 to 8 mg/kg/day but not 10 to 12 mg/kg/day. MICs for Dapr strains ranged from 8 to 256 mg/liter. Some S613 derivatives developed mutations in liaF or cls. S447 derivatives lacked mutations in these genes. Dapr derivatives from both strains exhibited lowered growth rates, up to a 72% reduction in daptomycin-induced depolarization and up to 6-nm increases in CWT (P<0.01). Peak/MIC and AUC0-24/MIC ratios (AUC0-24 is the area under the concentration-time curve from 0 to 24 h) associated with Dapr prevention were 72.1 and 780 for S447 and 144 and 1561 for S613, respectively. Daptomycin doses of 10 mg/kg/day may be required to prevent Dapr in serious enterococcal infections.

Indexed as

Anti-Bacterial AgentsDaptomycinDose-Response Relationship, DrugDrug Resistance, NeoplasmEnterococcus faecalisEnterococcus faeciumGram-Positive Bacterial InfectionsHumansMicrobial Sensitivity TestsVancomycin ResistanceAnti-Bacterial AgentsDaptomycin

Identifiers

PMID24957825
PMCPMC4135850
OpenAlexW2104843654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.